P.b.p Enterprises Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: P.b.p Enterprises Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $9.7K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

P.b.p Enterprises Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $9.7K Trade | TransData Nexus

P.b.p Enterprises Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $9.7K Total Trade · DGFT Verified

P.b.p Enterprises Private Limited is an Indian pharmaceutical exporter with a total trade value of $9.7K across 2 products in 2 therapeutic categories. Based on 7 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Regorafenib ($7.9K), Atovaquone ($1.8K), .

P.b.p Enterprises Private Limited — Export Portfolio & Destination Treemap

P.b.p Enterprises Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is P.b.p Enterprises Private Limited? — Company Overview & Market Position

P.B.P Enterprises Private Limited is an Indian pharmaceutical exporter headquartered in Mumbai, Maharashtra. Established on August 21, 2018, the company operates under the Corporate Identification Number (CIN) U51909MH2018PTC312925. It is a private, unlisted entity with an authorized and paid-up capital of ₹500,000 each. The company's registered office is located at 10, Floor Grd, Plot 65, Ganapati Bhavan, Mahatma Jyotiba Phule Road, Naigaon Dadar East, Mumbai, Maharashtra, 400014.

P.B.P Enterprises specializes in the wholesale trading of pharmaceutical products, focusing on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. The company has been operational since its incorporation in 2018 and has been actively involved in the export of pharmaceutical products.

What Does P.b.p Enterprises Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Regorafenib$7.9K 2Atovaquone

Product Portfolio — Top 2 by Export Value

P.b.p Enterprises Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Regorafenib	Advanced Oncology	$7.9K	3	0.8%	7
2	Atovaquone	Antimalarial & Antiparasitic	$1.8K	4	0.0%	10

P.b.p Enterprises Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $9.7K. The top category is Advanced Oncology (81.1% of portfolio), followed by Antimalarial & Antiparasitic (18.9%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

P.b.p Enterprises Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

P.B.P Enterprises Private Limited does not own manufacturing facilities. Instead, it operates as a trader and wholesaler, sourcing pharmaceutical products from various manufacturers. The company emphasizes quality assurance by personally testing each batch of medications to ensure compliance with FDA standards. This approach allows P.B.P Enterprises to offer a broad range of pharmaceutical goods, including anti-cancer drugs, HIV medications, and nephrology drugs, without the overhead associated with manufacturing.

3Key Leadership

The leadership team at P.B.P Enterprises Private Limited comprises:

Deepak Prakash Shete: Director
Durvank Mohan Kamerkar: Director
Gaurav Prakash Kamerkar: Director

These individuals have been instrumental in steering the company's operations and strategic direction since its inception.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does P.b.p Enterprises Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

P.B.P Enterprises Private Limited's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has engaged in exporting products such as Regorafenib and Atovaquone, indicating a presence in therapeutic areas like oncology and infectious diseases. However, specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. This lack of publicly accessible information suggests that P.B.P Enterprises may not have established a significant presence in these regulated markets.

2Emerging Markets

P.B.P Enterprises Private Limited has been involved in exporting pharmaceutical products to various regions, including Africa, Latin America, and Southeast Asia. The company's engagement in these markets is facilitated by its adherence to international quality standards, ensuring that its products meet the necessary criteria for distribution in these regions. While specific details about WHO prequalification or other certifications are not publicly disclosed, the company's commitment to quality suggests a focus on meeting global standards to enhance market access.

3Geographic Strategy

P.b.p Enterprises Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding P.B.P Enterprises Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. This absence of publicly accessible data suggests that the company may not have established a significant presence in the U.S. market or may not have pursued FDA approvals for its products. Without FDA approvals, the company's ability to market and distribute its pharmaceutical products in the United States would be limited.

2WHO & EU GMP

There is no publicly available information indicating that P.B.P Enterprises Private Limited holds WHO prequalification or EU Good Manufacturing Practice (GMP) certificates. The absence of such certifications may limit the company's ability to export its products to markets that require these standards. Obtaining WHO prequalification and EU GMP certifications could enhance the company's credibility and facilitate access to a broader range of international markets.

3CDSCO & Indian Regulatory

P.b.p Enterprises Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

P.B.P Enterprises Private Limited operates in a competitive pharmaceutical export market, with numerous companies offering similar products. While specific market share data is not publicly available, the company's focus on high-demand therapeutic areas such as oncology and infectious diseases positions it in a competitive segment. To enhance its competitive edge, P.B.P Enterprises could consider diversifying its product portfolio, obtaining international certifications, and expanding its presence in regulated markets.

2Key Differentiators

P.B.P Enterprises Private Limited's key differentiators include its specialization in finished pharmaceutical formulations and its commitment to quality assurance. The company's focus on high-demand therapeutic areas such as oncology and infectious diseases allows it to cater to critical healthcare needs. Additionally, P.B.P Enterprises' adherence to international quality standards, as evidenced by its compliance with FDA norms, enhances its credibility in the pharmaceutical export market.

3Strategic Position

P.B.P Enterprises Private Limited's current strategic direction appears to be focused on trading and wholesaling finished pharmaceutical formulations, with an emphasis on high-demand therapeutic areas. The company's future outlook could benefit from expanding its product portfolio, obtaining international certifications such as WHO prequalification and EU GMP, and exploring new markets to mitigate risks associated with product concentration and enhance growth prospects.

Buyer Due Diligence Brief — Evaluating P.b.p Enterprises Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

P.B.P Enterprises Private Limited has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $10,000 USD across seven shipments. The company's focus on high-demand therapeutic areas and its commitment to quality assurance indicate reliability in its operations. However, the concentration of its export portfolio in a limited number of products suggests that the company may benefit from diversifying its offerings to enhance resilience and reduce dependency on specific products.

2Certifications to Verify

Importers should verify the following certifications when considering P.B.P Enterprises Private Limited as a supplier:

FDA Facility Registration: To confirm compliance with U.S. regulatory standards.
WHO Prequalification: To ensure adherence to international quality standards.
EU GMP Certification: To verify compliance with European manufacturing standards.

Frequently Asked Questions — P.b.p Enterprises Private Limited

How many pharmaceutical products does P.b.p Enterprises Private Limited export from India?

P.b.p Enterprises Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Regorafenib ($7.9K), Atovaquone ($1.8K). Total export value is $9.7K.

What is P.b.p Enterprises Private Limited's total pharmaceutical export value?

P.b.p Enterprises Private Limited's total pharmaceutical export value is $9.7K, based on 7 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does P.b.p Enterprises Private Limited cover?

P.b.p Enterprises Private Limited exports across 2 therapeutic categories. The largest are Advanced Oncology (81.1%, 1 products), Antimalarial & Antiparasitic (18.9%, 1 products).

Get Full P.b.p Enterprises Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.